Anavex Life Sciences Corp (AVXL)

[Steady_T]

The company had to exhaust the EMA process. The reexam, on the chance there would be a CMA and to find out what all the issues are as the EMA sees them.
That knowledge is important in moving ahead with the FDA.

As far as starting other trials, the path forward would look very different if there had been a CMA than it does now that the company can't expect an immediate revenue stream. I expect that the company has been developing plans for both contingencies.

We will see in the near future if that is the case by what the company does and how quickly it does it.